Traders assign an 81.5% chance that no new COVID variant of concern will emerge before 2027 because SARS-CoV-2 continues to evolve mainly through Omicron sublineages under active genomic surveillance. Recent detections of highly mutated strains such as BA.3.2, first identified in late 2024 and rising modestly through early 2026, have shown limited spread and no meaningful rise in hospitalizations or disease severity. Health authorities classify these as variants under monitoring rather than variants of concern, reflecting stable population immunity from prior infections and updated vaccines. Ongoing wastewater and traveler-based tracking shows these lineages remain at low prevalence without the immune-escape or transmissibility jumps that previously triggered higher alerts. This pattern of gradual adaptation without disruptive shifts underpins the current market pricing.